Perioperative administration of high-dose recombinant human erythropoietin for delayed graft function prevention in kidney transplantation: A meta-analysis

Transplant International

Volumn 28, Issue 3, 2015, Pages 330-340

  Vlachopanos, Georgios ^a   Kassimatis, Theodoros I ^a   Agrafiotis, Athanasios ^a  

^a IASO GENERAL HOSPITAL   (Greece)

Author keywords

delayed graft function; erythropoietin; kidney transplantation; meta analysis

Indexed keywords

PLACEBO; RECOMBINANT ERYTHROPOIETIN; ANTIANEMIC AGENT;

ARTICLE; CARDIOVASCULAR RISK; DELAYED GRAFT FUNCTION; DRUG EFFECT; DRUG MEGADOSE; HUMAN; KIDNEY TRANSPLANTATION; META ANALYSIS; PERIOPERATIVE PERIOD; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL (TOPIC); RENAL PROTECTION; SYSTOLIC BLOOD PRESSURE; DOSE RESPONSE; GRAFT SURVIVAL; PROCEDURES; RISK FACTOR;

DELAYED GRAFT FUNCTION; DOSE-RESPONSE RELATIONSHIP, DRUG; EPOETIN ALFA; GRAFT SURVIVAL; HEMATINICS; HUMANS; KIDNEY TRANSPLANTATION; PERIOPERATIVE CARE; RISK FACTORS;

EID: 84925456279     PISSN: 09340874     EISSN: 14322277     Source Type: Journal    
DOI: 10.1111/tri.12506     Document Type: Article

References (37)

1. Wolfe RA, Ashby VB, Milford EL, et al,. Comparison of mortality in all patients on dialysis, patients on dialysis awaiting transplantation, and recipients of a first cadaveric transplant. N Engl J Med 1999; 341: 1725.
2. Neipp M, Karavul B, Jackobs S, et al,. Quality of life in adult transplant recipients more than 15 years after kidney transplantation. Transplantation 2006; 81: 1640.
3. Summers DM, Johnson RJ, Allen J, et al,. Analysis of factors that affect outcome after transplantation of kidneys donated after cardiac death in the UK: a cohort study. Lancet 2010; 376: 1303.
4. Yarlagadda SG, Coca SG, Formica RN Jr, Poggio ED, Parikh CR,. Association between delayed graft function and allograft and patient survival: a systematic review and meta-analysis. Nephrol Dial Transplant 2009; 24: 1039.
5. Jelkmann W,. Molecular biology of erythropoietin. Intern Med 2004; 43: 649.
6. Eschbach JW, Egrie JC, Downing MR, Browne JK, Adamson JW,. Correction of the anemia of end-stage renal disease with recombinant human erythropoietin. Results of a combined phase I and II clinical trial. N Engl J Med 1987; 316: 73.
7. Forman CJ, Johnson DW, Nicol DL,. Erythropoietin administration protects against functional impairment and cell death after ischaemic renal injury in pigs. BJU Int 2007; 99: 162.
8. Sharples EJ, Patel N, Brown P, et al,. Erythropoietin protects the kidney against the injury and dysfunction caused by ischemia-reperfusion. J Am Soc Nephrol 2004; 15: 2115.
9. Brines M, Cerami A,. Erythropoietin-mediated tissue protection: reducing collateral damage from the primary injury response. J Intern Med 2008; 264: 405.
10. Binbrek AS, Rao NS, Al Khaja N, Assaqqaf J, Sobel BE,. Erythropoietin to augment myocardial salvage induced by coronary thrombolysis in patients with ST segment elevation acute myocardial infarction. Am J Cardiol 2009; 104: 1035.
11. Cariou A, Claessens YE, Pène F, et al,. Early high-dose erythropoietin therapy and hypothermia after out-of-hospital cardiac arrest: a matched control study. Resuscitation 2008; 76: 397.
12. Brines M, Grasso G, Fiordaliso F, et al,. Erythropoietin mediates tissue protection through an erythropoietin and common beta-subunit heteroreceptor. Proc Natl Acad Sci USA 2004; 101: 14907.
13. Tapiawala SN, Tinckam KJ, Cardella CJ, et al,. Delayed graft function and the risk for death with a functioning graft. J Am Soc Nephrol 2010; 21: 153.
14. Ojo AO, Wolfe RA, Held PJ, Port FK, Schmouder RL,. Delayed graft function: risk factors and implications for renal allograft survival. Transplantation 1997; 63: 968.
15. Higgins JP, Altman DG, Gøtzsche PC, et al,. Cochrane Statistical Methods Group. The Cochrane Collaboration's tool for assessing risk of bias in randomised trials. BMJ 2011; 18: d5928.
16. Guyatt G, Oxman AD, Akl EA, et al,. GRADE guidelines: 1. Introduction-GRADE evidence profiles and summary of findings tables. J Clin Epidemiol 2011; 64: 383.
17. Campistol JM, Carreño A, Morales JM, et al,. Once-monthly pegylated epoetin beta versus darbepoetin alfa every two weeks in renal transplant recipients: a randomized trial. Transplantation 2013; 95: e6.
18. Choukroun G, Kamar N, Dussol B, et al,. Correction of postkidney transplant anemia reduces progression of allograft nephropathy. J Am Soc Nephrol 2012; 23: 360.
19. Bartels V, Hillebrand U, Kosch M, et al,. Influence of erythropoietin on arterial stiffness and endothelial function in renal transplant recipients. Am J Nephrol. 2012; 36: 355.
20. Beiraghdar F, Panahi Y, Einollahi B, et al,. Investigation of the efficacy of a biogeneric recombinant human erythropoietin alfa in the correction of post-transplantation anemia: a randomized comparative trial with Eprex. Clin Lab 2012; 58: 1179.
21. Pankewycz O, Kulaylat M, Fagan L, Matthews B, Kohli R, Laftavi MR,. A prospective protocol-based trial of darbepoetin alfa therapy to correct the early anemia following renal transplantation. Transplant Proc 2010; 42: 3537.
22. Roger SD, Suranyi MG, Walker RG, et al,. A randomised, cross-over study comparing injection site pain with subcutaneous epoetin beta and subcutaneous darbepoetin alfa in patients with chronic kidney disease. Curr Med Res Opin 2008; 24: 2181.
23. Van Biesen W, Vanholder R, Veys N, Verbeke F, Lameire N,. Efficacy of erythropoietin administration in the treatment of anemia immediately after renal transplantation. Transplantation 2005; 79: 367.
24. Van Loo A, Vanholder R, Bernaert P, De Roose J, Lameire N,. Recombinant human erythropoietin corrects anaemia during the first weeks after renal transplantation: a randomized prospective study. Nephrol Dial Transplant 1996; 11: 1815.
25. Yasari F, Nafar M, Alipour Abdei B, et al,. Effect of erythropoietin on kidney allograft survival: early use after transplantation. Iran J Kidney Dis 2012; 6: 44.
26. Martinez F, Kamar N, Pallet N, et al,. High dose epoetin beta in the first weeks following renal transplantation and delayed graft function: Results of the Neo-PDGF Study. Am J Transplant 2010; 10: 1695.
27. Hafer C, Becker T, Kielstein JT, et al,. High-dose erythropoietin has no effect on short- or long-term graft function following deceased donor kidney transplantation. Kidney Int 2012; 81: 314.
28. Aydin Z, Mallat MJ, Schaapherder AF, et al,. Randomized trial of short-course high-dose erythropoietin in donation after cardiac death kidney transplant recipients. Am J Transplant 2012; 12: 1793.
29. Sureshkumar KK, Hussain SM, Ko TY, Thai NL, Marcus RJ,. Effect of high-dose erythropoietin on graft function after kidney transplantation: a randomized, double-blind clinical trial. Clin J Am Soc Nephrol 2012; 7: 1498.
30. Irish WD, McCollum DA, Tesi RJ, et al,. Nomogram for predicting the likelihood of delayed graft function in adult cadaveric renal transplant recipients. J Am Soc Nephrol 2003; 14: 2967.
31. Jiang S, Chen Y, Zou J, et al,. Diverse effects of ischemic pretreatments on the long-term renal damage induced by ischemia-reperfusion. Am J Nephrol 2009; 30: 440.
32. Bahlmann FH, Song R, Boehm SM, et al,. Low-dose therapy with the long-acting erythropoietin analogue darbepoetin alpha persistently activates endothelial Akt and attenuates progressive organ failure. Circulation 2004; 110: 1006.
33. De Beuf A, D'Haese PC, Verhulst A,. Epoetin delta as an antifibrotic agent in the remnant kidney rat: a possible role for transforming growth factor beta and hepatocyte growth factor. Nephron Exp Nephrol 2010; 115: e46.
34. Cravedi P, Manrique J, Hanlon KE, et al,. Immunosuppressive effects of erythropoietin on human alloreactive T cells. J Am Soc Nephrol 2014; 25: 2003.
35. Imamura R, Isaka Y, Ichimaru N, Takahara S, Okuyama A,. Carbamylated erythropoietin protects the kidneys from ischemia-reperfusion injury without stimulating erythropoiesis. Biochem Biophys Res Commun 2007; 353: 786.
36. Nijboer WN, Ottens PJ, van Dijk A, van Goor H, Ploeg RJ, Leuvenink HG,. Donor pretreatment with carbamylated erythropoietin in a brain death model reduces inflammation more effectively than erythropoietin while preserving renal function. Crit Care Med 2010; 38: 1155.
37. van Rijt WG, Nieuwenhuijs-Moeke GJ, van Goor H, et al,. ARA290, a non-erythropoietic rHuEPO derivative, attenuates renal ischemia/reperfusion injury. J Transl Med 2013; 9: 9.